IMCR Insider Trading
Insider Ownership Percentage: 9.10%
Insider Buying (Last 12 Months): $23,994,085.36
Insider Selling (Last 12 Months): $0.00
Immunocore Insider Trading History Chart
This chart shows the insider buying and selling history at Immunocore by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Immunocore Share Price & Price History
Current Price: $29.64
Price Change: ▼ Price Decrease of -0.17 (-0.57%)
As of 03/24/2025 05:00 PM ET
Immunocore Insider Trading History
Immunocore Institutional Trading History
Data available starting January 2016
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More on Immunocore
Today's Range
Now: $29.64
52 Week Range
Now: $29.64
Volume
377,414 shs
Average Volume
436,082 shs
Market Capitalization
$1.48 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.79
Who are the company insiders with the largest holdings of Immunocore?
Who are the major institutional investors of Immunocore?
Immunocore's top institutional investors include:
- T. Rowe Price Investment Management Inc. — 13.39%
- Wellington Management Group LLP — 13.23%
- FMR LLC — 9.63%
- Primecap Management Co. CA — 5.33%
- Price T Rowe Associates Inc. MD — 4.37%
- Tang Capital Management LLC — 3.11%
Learn More about top institutional investors of Immunocore stock.
Which major investors are selling Immunocore stock?
During the last quarter, IMCR stock was sold by these institutional investors:
- Wellington Management Group LLP
- Polar Capital Holdings Plc
- Two Sigma Investments LP
- Renaissance Technologies LLC
- Marshall Wace LLP
- Two Sigma Advisers LP
- Millennium Management LLC
- Bank of America Corp DE
Which major investors are buying Immunocore stock?
In the previous quarter, IMCR stock was acquired by institutional investors including:
- Groupama Asset Managment
- Deep Track Capital LP
- Tang Capital Management LLC
- Point72 Asset Management L.P.
- T. Rowe Price Investment Management Inc.
- Primecap Management Co. CA
- BNP Paribas Financial Markets
- Jefferies Financial Group Inc.